* This is the Professional Version. *
Assisted Reproductive Techniques
Assisted reproductive techniques (ARTs) involve manipulation of sperm and ova or embryos in vitro with the goal of producing a pregnancy.
ARTs may result in multifetal pregnancy, but risk is much less than that with controlled ovarian hyperstimulation. If risk of genetic defects is high, the embryo can often be tested for defects before transfer and implantation (preimplantation genetic diagnosis).
IVF can be used to treat infertility due to oligospermia, sperm antibodies, tubal dysfunction, or endometriosis as well as unexplained infertility.
The procedure typically involves the following:
Controlled ovarian hyperstimulation: Clomiphene plus gonadotropins or gonadotropins alone can be used. A gonadotropin-releasing hormone (GnRH) agonist or antagonist is often given to prevent premature ovulation. After sufficient follicular growth, human chorionic gonadotropin (hCG) is given to trigger final follicular maturation and ovulation.
Oocyte retrieval: About 34 h after hCG is given, oocytes are retrieved by direct needle puncture of the follicle, usually transvaginally with ultrasound guidance or less commonly laparoscopically. At some centers, natural cycle IVF (in which a single oocyte is retrieved) is offered as an alternative; pregnancy rates with this technique are lower than those with retrieval of multiple oocytes, but costs are lower and success rates are increasing.
Fertilization: The oocytes are inseminated in vitro. The semen sample is typically washed several times with tissue culture medium and is concentrated for motile sperm, which are then added.
Embryo culture: After sperm are added, the oocytes are cultured for about 2 to 5 days.
Embryo transfer: Only 1 or a few of the resulting embryos are transferred to the uterine cavity, minimizing the chance of a multifetal pregnancy, the greatest risk of IVF. The number of embryos transferred is determined by the woman’s age and likelihood of response to IVF. Other embryos may be frozen in liquid nitrogen for transfer in a subsequent cycle.
Birth defects may be slightly more common after IVF, but experts are uncertain whether the increased risk is due to IVF or to factors contributing to infertility; infertility itself increases risk of birth defects. Still, as of mid-2014, the overwhelming majority of the > 5 million children born after IVF have no birth defects.
Preimplantation genetic diagnosis (PGD) can be done; individual blastomeres from blastocysts can be tested before transfer to check for specific serious hereditary disorders (see Genetic Evaluation). If test results are delayed, the blastocyst can be frozen and transferred in a later cycle after the results are known.
In women < 35, about 46% of IVF cycles result in pregnancy, and 87% of the pregnancies end in live births in the US (2011 data). The pregnancy rate decreases with increasing age; for women aged 41 to 42, the pregnancy rate is 19.4%, and only about 62% of these pregnancies end in live births. Use of donor oocytes is usually recommended for women >42.
GIFT is an alternative to IVF but is being used less and less frequently because success rates for IVF have increased.
GIFT is used most often when women have one of the following:
Multiple oocytes and sperm are obtained as for IVF but are transferred—transvaginally with ultrasound guidance or laparoscopically—to the distal fallopian tubes, where fertilization occurs.
Live birth rates per cycle are about 25 to 35% at most infertility centers.
This technique is useful when
Oocytes are obtained as for IVF. A single sperm is injected into each oocyte to avoid fertilization by abnormal sperm. The embryo is then cultured and transferred as for IVF.
In 2011, about two thirds of all ART cycles in the US involved intracytoplasmic sperm injection.
Risk of birth defects may be increased after intracytoplasmic sperm injection, possibly because the following:
Other techniques are sometimes used. They include the following:
Some of these techniques raise moral and ethical issues (eg, rightful parentage in surrogate motherhood, selective reduction of the number of implanted embryos if multifetal pregnancy results).
Drug NameSelect Trade
* This is the Professional Version. *